Aran Singanayagam

Aran Singanayagam

Auto-generated profile, based on publicly available information

Aran Singanayagam

Imperial College London

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in The American Journal of Medicine
Verified
Journal Article
Closed access
JCJames D. Chalmers
James D. Chalmers
ASAran Singanayagam
Aran Singanayagam
AHAdam T. Hill
Adam T. Hill

20 August 2010 in Thorax
Verified
Journal Article
Closed access
PDF file
JCJames D Chalmers
James D Chalmers
ASAran Singanayagam
Aran Singanayagam
AAAhsan AKRAM
Ahsan AKRAM
PMPallavi Mandal
Pallavi Mandal
PSPhilip M Short
Philip M Short
AHAdam T Hill
Adam T Hill
Introduction International guidelines recommend a severity-based approach to management in community-acquired pneumonia. CURB65, CRB65 and the Pneumonia Severity Index (PSI) are the most widely recommended severity scores. The aim of this study was to compare the performance characteristics of these scores for predicting mortality in community-acquired pneumonia. Methods A systematic review and meta-analysis was conducted according to MOOSE (meta-analysis of observational studies in epidemiology) guidelines. PUBMED and EMBASE were searched (1980–2009). 40 studies reporting prognostic information for the PSI, CURB65 and CRB65 severity scores were identified. Performance characteristics were pooled using a random effects model. Relationships between sensitivity and specificity were plotted using summary receiver operator characteristic (sROC) curves. Results All three scores predicted 30 day mortality. The PSI had the highest area under the sROC curve, 0.81 (SE 0.008), compared with CURB65, 0.80 (SE 0.008), p=0.1, and CRB65, 0.79 (0.01), p=0.09. These differences were not statistically significant. Performance characteristics were similar across comparable cut-offs for low, intermediate and high risk for each score. In identifying low risk patients, PSI (groups I and II) had the best negative likelihood ratio 0.08 (0.06–0.12) compared with CURB65 (score 0–1) 0.21 (0.15–0.30) and CRB65 (score 0), 0.15 (0.10–0.22). Conclusion There were no significant differences in overall test performance between PSI, CURB65 and CRB65 for predicting mortality from community-acquired pneumonia.

1 April 2013 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
ASAran Singanayagam
Aran Singanayagam
SSStuart Schembri
Stuart Schembri
JCJames D. Chalmers
James D. Chalmers
There is a need to identify clinically meaningful predictors of mortality following hospitalized COPD exacerbation. The aim of this study was to systematically review the literature to identify clinically important factors that predict mortality after hospitalization for acute exacerbation of chronic obstructive pulmonary disease (COPD). Eligible studies considered adults admitted to hospital with COPD exacerbation. Two authors independently abstracted data. Odds ratios were then calculated by comparing the prevalence of each predictor in survivors versus nonsurvivors. For continuous variables, mean differences were pooled by the inverse of their variance, using a random effects model. There were 37 studies included (189,772 study subjects) with risk of death ranging from 3.6% for studies considering short-term mortality, 31.0% for long-term mortality (up to 2 yr after hospitalization), and 29.0% for studies that considered solely intensive care unit (ICU)-admitted study subjects. Twelve prognostic factors (age, male sex, low body mass index, cardiac failure, chronic renal failure, confusion, long-term oxygen therapy, lower limb edema, Global Initiative for Chronic Lung Disease criteria stage 4, cor pulmonale, acidemia, and elevated plasma troponin level) were significantly associated with increased short-term mortality. Nine prognostic factors (age, low body mass index, cardiac failure, diabetes mellitus, ischemic heart disease, malignancy, FEV1, long-term oxygen therapy, and PaO2 on admission) were significantly associated with long-term mortality. Three factors (age, low Glasgow Coma Scale score, and pH) were significantly associated with increased risk of mortality in ICU-admitted study subjects. Different factors correlate with mortality from COPD exacerbation in the short term, long term, and after ICU admission. These parameters may be useful to develop tools for prediction of outcome in clinical practice.

1 April 2020 in The Lancet
Verified
Journal Article
Closed access
ARAndrew I Ritchie
Andrew I Ritchie
ASAran Singanayagam
Aran Singanayagam

20 June 2011 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JCJames D. Chalmers
James D. Chalmers
JTJoanne K. Taylor
Joanne K. Taylor
ASAran Singanayagam
Aran Singanayagam
GFGillian B. Fleming
Gillian B. Fleming
AAAhsan AKRAM
Ahsan AKRAM
AHAdam T. Hill
Adam T. Hill
Background. The recently introduced concept of health care–associated pneumonia (HCAP), referring to patients with frequent healthcare contacts and at higher risk of contracting resistant pathogens, is controversial.

8 June 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAran Singanayagam
Aran Singanayagam
NGNicholas Glanville
Nicholas Glanville
JGJason L. Girkin
Jason L. Girkin
YCYee Man Ching
Yee Man Ching
AMAndrea Marcellini
Andrea Marcellini
SJSebastian L Johnston
Sebastian L Johnston
Inhaled corticosteroids (ICS) have limited efficacy in reducing chronic obstructive pulmonary disease (COPD) exacerbations and increase pneumonia risk, through unknown mechanisms. Rhinoviruses precipitate most exacerbations and increase susceptibility to secondary bacterial infections. Here, we show that the ICS fluticasone propionate (FP) impairs innate and acquired antiviral immune responses leading to delayed virus clearance and previously unrecognised adverse effects of enhanced mucus, impaired antimicrobial peptide secretion and increased pulmonary bacterial load during virus-induced exacerbations. Exogenous interferon-β reverses these effects. FP suppression of interferon may occur through inhibition of TLR3- and RIG-I virus-sensing pathways. Mice deficient in the type I interferon-α/β receptor (IFNAR1−/−) have suppressed antimicrobial peptide and enhanced mucin responses to rhinovirus infection. This study identifies type I interferon as a central regulator of antibacterial immunity and mucus production. Suppression of interferon by ICS during virus-induced COPD exacerbations likely mediates pneumonia risk and raises suggestion that inhaled interferon-β therapy may protect.